Company intelligence / Profile preview
Sinotau Pharmaceutical Group
- Ownership
- Private
- Development stage
- Commercial
Overview
Sinotau has successfully commercialized Florbetaben F 18 injection (Neuraceq®/欧韦宁®), the first amyloid PET tracer approved in China for Alzheimer's disease diagnosis. The company has over 20 novel products in different development stages, including Phase 3 trials for Florquinitau F18 for mild cognitive disorders and Phase 2/3 trials for Lutetium Dotatate LU-177 for neuroendocrine tumors.
- Therapeutic areas
- OncologyCardiovascularNeurology
- Modalities
- Diagnostic radiopharmaceuticalsTherapeutic radiopharmaceuticalsSmall molecule drugsPeptide Conjugate Radionuclide
- Industry
- Biotech
Drug pipeline
20 assets19 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Sinotau Pharmaceutical Group.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sinotau Pharmaceutical Group.